Contact
/
Home
/
About
Team
Portfolio
Exit History
News
About
Team
Portfolio
Exit History
News
Advent Life Sciences
Advent Life Sciences
Page 3 of 24
<< Start
< Prev
1
2
3
4
5
6
7
8
9
10
Next >
End >>
15.11.2021
Aura Biosciences Presents Final Phase 1b/2 Data for its first Virus-Like Drug Conjugate, AU-011, in Patients with Choroidal Melanoma at the American Academy of Ophthalmology
Press Release
12.11.2021
Highlight Therapeutics announces positive preliminary results from Phase 2b study of BO-112 + anti-PD1 in confirmed anti-PD1 progressor melanoma patients at SITC
Press Release
01.11.2021
Amphista Therapeutics Appoints CBO, Beverley Carr
Press Release
28.10.2021
Aura Biosciences Announces Pricing of Initial Public Offering
Press Release
11.10.2021
Aura Biosciences Presents Interim Phase 2 Safety Data Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanoma at the ASRS 2021 Annual Meeting
Press Release
29.09.2021
Aura Biosciences Expands Executive Leadership Team and Board of Directors
Press Release
21.09.2021
Dr. Carolin Barth Joins MiroBio as CEO to Lead Precision Immunology Company Focused on Checkpoint Agonist Antibodies
Press Release
21.09.2021
Amphista Therapeutics Appoints New Chairman, Joshua T. Brumm
Press Release
15.09.2021
Rappta Therapeutics Appoints Sunjeet Sawhney as Chief Executive Officer
Press Release
09.09.2021
Eloxx Pharmaceuticals Announces Fast Track Designation for ELX-02 for the Treatment of Cystic Fibrosis Patients with Nonsense Mutations
Press Release
©2022 Advent Life Sciences